CS201014B2 - Process for preparing new analoges of angiotensine ii with residue of alpha-aminooxyacid in position 1 - Google Patents

Process for preparing new analoges of angiotensine ii with residue of alpha-aminooxyacid in position 1 Download PDF

Info

Publication number: CS201014B2
Authority: CS; Czechoslovakia
Prior art keywords: group; solution; acid; formula; ether
Prior art date: 1977-07-18

Application number

CS784758A

Other languages

Czech (cs)

English (en)

Inventor

Lajos Kisfaludy

Gyorgy Nyeki

Laszlo Szirmai

Egon Karpati

Katalin Gidai

Laszlo Szporny

Original Assignee

Richter Gedeon Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-07-18

Filing date

1978-07-17

Publication date

1980-10-31

1978-07-17 Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet

1980-10-31 Publication of CS201014B2 publication Critical patent/CS201014B2/cs

Links

238000004519 manufacturing process Methods 0.000 title description 2
JYPVVOOBQVVUQV-CGHBYZBKSA-N angiotensinamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 JYPVVOOBQVVUQV-CGHBYZBKSA-N 0.000 title 1
239000002253 acid Substances 0.000 claims abstract description 15
125000001931 aliphatic group Chemical group 0.000 claims abstract description 11
150000003839 salts Chemical class 0.000 claims abstract description 11
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims abstract 2
150000001875 compounds Chemical class 0.000 claims description 27
238000000034 method Methods 0.000 claims description 13
-1 aliphatic amino acid Chemical class 0.000 claims description 12
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
230000002378 acidificating effect Effects 0.000 claims description 4
230000009471 action Effects 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 3
150000007513 acids Chemical class 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
230000003213 activating effect Effects 0.000 claims description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
230000001052 transient effect Effects 0.000 claims description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
240000000260 Typha latifolia Species 0.000 claims 1
150000003862 amino acid derivatives Chemical class 0.000 claims 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
150000001413 amino acids Chemical class 0.000 abstract description 8
206010020772 Hypertension Diseases 0.000 abstract description 4
102100028255 Renin Human genes 0.000 abstract description 4
108090000783 Renin Proteins 0.000 abstract description 4
230000003042 antagnostic effect Effects 0.000 abstract description 4
238000003745 diagnosis Methods 0.000 abstract description 2
239000000243 solution Substances 0.000 description 80
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 78
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 44
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 39
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
239000000203 mixture Substances 0.000 description 20
CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 18
108090000765 processed proteins & peptides Proteins 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
102400000345 Angiotensin-2 Human genes 0.000 description 11
101800000733 Angiotensin-2 Proteins 0.000 description 11
229950006323 angiotensin ii Drugs 0.000 description 11
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
238000001704 evaporation Methods 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
230000036772 blood pressure Effects 0.000 description 9
238000001035 drying Methods 0.000 description 9
230000008020 evaporation Effects 0.000 description 9
239000000047 product Substances 0.000 description 8
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 7
125000006239 protecting group Chemical group 0.000 description 7
229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 6
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
230000000694 effects Effects 0.000 description 6
229920000159 gelatin Polymers 0.000 description 6
235000019322 gelatine Nutrition 0.000 description 6
229910000040 hydrogen fluoride Inorganic materials 0.000 description 6
239000002904 solvent Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
WBIIPXYJAMICNU-AWEZNQCLSA-N (2s)-5-[amino-[(4-methylphenyl)sulfonylamino]methylidene]azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC1=CC=C(S(=O)(=O)NC(N)=NCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C=C1 WBIIPXYJAMICNU-AWEZNQCLSA-N 0.000 description 4
239000001828 Gelatine Substances 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
239000005695 Ammonium acetate Substances 0.000 description 3
229940043376 ammonium acetate Drugs 0.000 description 3
235000019257 ammonium acetate Nutrition 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
238000011160 research Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000011877 solvent mixture Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
LHMQOAPYTSAHML-LBPRGKRZSA-N (2,3,4,5,6-pentafluorophenyl) (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](C(C)C)C(=O)OC1=C(F)C(F)=C(F)C(F)=C1F LHMQOAPYTSAHML-LBPRGKRZSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
241000965481 Darksidea alpha Species 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
JTXJZBMXQMTSQN-UHFFFAOYSA-N amino hydrogen carbonate Chemical class NOC(O)=O JTXJZBMXQMTSQN-UHFFFAOYSA-N 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 1
NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical group NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 description 1
AHIBSEICBQMMDB-UHFFFAOYSA-N 2-aminooxypropanoic acid Chemical compound NOC(C)C(O)=O AHIBSEICBQMMDB-UHFFFAOYSA-N 0.000 description 1
MSYNCHLYGJCFFY-UHFFFAOYSA-B 2-hydroxypropane-1,2,3-tricarboxylate;titanium(4+) Chemical compound [Ti+4].[Ti+4].[Ti+4].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O MSYNCHLYGJCFFY-UHFFFAOYSA-B 0.000 description 1
NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
GGZZISOUXJHYOY-UHFFFAOYSA-N 8-amino-4-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C(N)=CC=CC2=C1O GGZZISOUXJHYOY-UHFFFAOYSA-N 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
101100148729 Caenorhabditis elegans sar-1 gene Proteins 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000004531 blood pressure lowering effect Effects 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
230000008859 change Effects 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
NYIODHFKZFKMSU-UHFFFAOYSA-N n,n-bis(methylamino)ethanamine Chemical compound CCN(NC)NC NYIODHFKZFKMSU-UHFFFAOYSA-N 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
239000011368 organic material Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
206010038464 renal hypertension Diseases 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
238000011268 retreatment Methods 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical group CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
125000001239 threonyl group Chemical group 0.000 description 1
VOITXYVAKOUIBA-UHFFFAOYSA-N triethylaluminium Chemical compound CC[Al](CC)CC VOITXYVAKOUIBA-UHFFFAOYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/14—Angiotensins: Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Vascular Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CS784758A 1977-07-18 1978-07-17 Process for preparing new analoges of angiotensine ii with residue of alpha-aminooxyacid in position 1 CS201014B2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU77RI640A HU177133B (en)	1977-07-18	1977-07-18	Process for preparing angiotensin ii analogues containing alpha- amino-oxy-acid in position 1 with angiotensin ii antagonist activity

Publications (1)

Publication Number	Publication Date
CS201014B2 true CS201014B2 (en)	1980-10-31

Family

ID=11001037

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS784758A CS201014B2 (en)	1977-07-18	1978-07-17	Process for preparing new analoges of angiotensine ii with residue of alpha-aminooxyacid in position 1

Country Status (24)

Country	Link
US (1)	US4179433A (pl)
JP (1)	JPS5835504B2 (pl)
AT (1)	AT361143B (pl)
AU (1)	AU518229B2 (pl)
BE (1)	BE869077A (pl)
CA (1)	CA1108124A (pl)
CH (1)	CH637915A5 (pl)
CS (1)	CS201014B2 (pl)
DD (1)	DD137220A5 (pl)
DE (1)	DE2831534C2 (pl)
DK (1)	DK319478A (pl)
ES (1)	ES471793A1 (pl)
FI (1)	FI64140C (pl)
FR (1)	FR2398050A1 (pl)
GB (1)	GB2001653B (pl)
HU (1)	HU177133B (pl)
IL (1)	IL55121A (pl)
IN (1)	IN149489B (pl)
NL (1)	NL7807676A (pl)
NO (1)	NO148031C (pl)
PL (1)	PL111979B1 (pl)
SE (1)	SE443790B (pl)
SU (1)	SU845773A3 (pl)
YU (1)	YU41431B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU181008B (en) *	1980-01-18	1983-05-30	Richter Gedeon Vegyeszet	Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
HU181009B (en) *	1980-01-18	1983-05-30	Richter Gedeon Vegyeszet	Process for preparing angiotensin-ii analogues with antagonictic activity containing in position 1 sarcosyl,hydroxyacetyl or l-alpha-aminoxy-propionyl group and in positiona 8 esteric group
HU191961B (en) *	1984-08-02	1987-04-28	Richter Gedeon Vegyeszet	Process for producing 1,5 and 8 substituted peptides of angiotenzin-ii antagonistic activity
US5036048A (en) *	1986-03-07	1991-07-30	Schering Corporation	Angiotensin II receptor blockers as antiglaucoma agents
US5182264A (en) *	1986-03-07	1993-01-26	Schering Corporation	Angiotensin II receptor blockers as antiglaucoma agents
US4772684A (en) *	1987-01-20	1988-09-20	Triton Biosciences, Inc.	Peptides affecting blood pressure regulation
TWI268138B (en) *	2000-05-11	2006-12-11	Kanebo Seiyaku Ltd	Composition containing peptide and electrolyte excretion enhancing substance, and food containing the same
AT508569A1 (de)	2009-07-23	2011-02-15	Affiris Ag	Pharmaceutical compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3886134A (en) *	1970-03-09	1975-05-27	Morton Norwich Products Inc	Analogues of angiotensin II
GB1320104A (en) *	1971-05-20	1973-06-13	Norwich Pharma Co	Hepta-and octapeptides
US3907762A (en) *	1971-12-27	1975-09-23	Univ Sherbrooke	Angiotensin{hd II {B position 8 analogs
HU167360B (pl) *	1972-08-25	1975-09-27
US3975365A (en) *	1975-01-27	1976-08-17	G. D. Searle & Co.	Inhibitory octapeptides angiotensin II
US3976770A (en) *	1975-02-10	1976-08-24	Francis Merlin Bumpus	Sar'-(OMe)Thr8 Angiotensin II as an angiotensin II antagonist

1977
- 1977-07-18 HU HU77RI640A patent/HU177133B/hu not_active IP Right Cessation
1978
- 1978-07-11 IL IL55121A patent/IL55121A/xx unknown
- 1978-07-11 US US05/923,681 patent/US4179433A/en not_active Expired - Lifetime
- 1978-07-13 SE SE7807823A patent/SE443790B/sv not_active IP Right Cessation
- 1978-07-13 AU AU38008/78A patent/AU518229B2/en not_active Expired
- 1978-07-13 CH CH762578A patent/CH637915A5/de not_active IP Right Cessation
- 1978-07-14 CA CA307,439A patent/CA1108124A/en not_active Expired
- 1978-07-14 FI FI782250A patent/FI64140C/fi not_active IP Right Cessation
- 1978-07-14 IN IN781/CAL/78A patent/IN149489B/en unknown
- 1978-07-14 DD DD78206733A patent/DD137220A5/xx unknown
- 1978-07-17 DK DK319478A patent/DK319478A/da not_active Application Discontinuation
- 1978-07-17 ES ES471793A patent/ES471793A1/es not_active Expired
- 1978-07-17 YU YU1713/78A patent/YU41431B/xx unknown
- 1978-07-17 SU SU782639399A patent/SU845773A3/ru active
- 1978-07-17 GB GB787830047A patent/GB2001653B/en not_active Expired
- 1978-07-17 FR FR7821136A patent/FR2398050A1/fr active Granted
- 1978-07-17 CS CS784758A patent/CS201014B2/cs unknown
- 1978-07-17 NO NO782463A patent/NO148031C/no unknown
- 1978-07-18 AT AT518478A patent/AT361143B/de not_active IP Right Cessation
- 1978-07-18 DE DE2831534A patent/DE2831534C2/de not_active Expired
- 1978-07-18 PL PL1978208496A patent/PL111979B1/pl unknown
- 1978-07-18 BE BE189343A patent/BE869077A/xx not_active IP Right Cessation
- 1978-07-18 NL NL7807676A patent/NL7807676A/xx not_active Application Discontinuation
- 1978-07-18 JP JP53087645A patent/JPS5835504B2/ja not_active Expired

Also Published As

Publication number	Publication date
FI782250A7 (fi)	1979-01-19
SU845773A3 (ru)	1981-07-07
GB2001653B (en)	1982-02-10
FR2398050B1 (pl)	1983-09-09
SE443790B (sv)	1986-03-10
CA1108124A (en)	1981-09-01
US4179433A (en)	1979-12-18
FI64140C (fi)	1983-10-10
ATA518478A (de)	1980-07-15
FI64140B (fi)	1983-06-30
YU171378A (en)	1983-01-21
YU41431B (en)	1987-06-30
AU518229B2 (en)	1981-09-17
CH637915A5 (de)	1983-08-31
BE869077A (fr)	1979-01-18
GB2001653A (en)	1979-02-07
DE2831534C2 (de)	1982-02-18
AT361143B (de)	1981-02-25
HU177133B (en)	1981-07-28
PL111979B1 (en)	1980-09-30
FR2398050A1 (fr)	1979-02-16
JPS5835504B2 (ja)	1983-08-03
PL208496A1 (pl)	1979-07-02
DE2831534A1 (de)	1979-02-01
NL7807676A (nl)	1979-01-22
IL55121A0 (en)	1978-09-29
AU3800878A (en)	1980-01-17
SE7807823L (sv)	1979-01-19
NO148031C (no)	1983-07-27
NO782463L (no)	1979-01-19
NO148031B (no)	1983-04-18
DK319478A (da)	1979-01-19
DD137220A5 (de)	1979-08-22
IL55121A (en)	1981-09-13
IN149489B (pl)	1981-12-26
ES471793A1 (es)	1979-02-01
JPS54119463A (en)	1979-09-17

Publication	Publication Date	Title
US4388304A (en)	1983-06-14	Angiotensin-II analogues with antagonizing effects, containing an ester group in position 8, and a process for the preparation thereof
KR0181512B1 (ko)	1999-04-01	펩티드 아미드, 이의 제조방법 및 피브린/트롬빈 응고 억제제로서 사용하기 위한 이를 함유하는 약제학적 조성물
JP2514518B2 (ja)	1996-07-10	ヘプタペプチドおよびオクタペプチドのソマトスタチン類似アミド誘導体、それを含有する抗腫瘍剤
KR100360639B1 (ko)	2003-01-30	N-치환글리신함유브라디키닌길항제펩티드
IE47421B1 (en)	1984-03-07	Somatostatin analogs,process for their preparation and pharmaceutical compositions containing them
EP0017746B1 (en)	1983-01-26	Peptides having somatostatin activity, compositions comprising them and process for making the peptides
WO1992015321A1 (en)	1992-09-17	Endothelin antagonists
RU2079509C1 (ru)	1997-05-20	Производные пептидов, обладающие способностью регулировать пролиферацию клеток, и способы ингибирования клеточной пролиферации человека и животного (варианты)
CS201014B2 (en)	1980-10-31	Process for preparing new analoges of angiotensine ii with residue of alpha-aminooxyacid in position 1
EP3914605B1 (en)	2022-12-07	Peptide precipitation method
US4209442A (en)	1980-06-24	Angiotensin II analogs and process for the preparation thereof
US5786335A (en)	1998-07-28	Sulfhydryl containing peptides for treating vascular disease
US3976770A (en)	1976-08-24	Sar'-(OMe)Thr8 Angiotensin II as an angiotensin II antagonist
US3925345A (en)	1975-12-09	(sar' 1',thr' 8'+9 angiotensin ii as an angiotensin antagonist
JPH06179697A (ja)	1994-06-28	ブラジキニン拮抗作用をもつ新規の擬似ペプチド化合物
RU2010799C1 (ru)	1994-04-15	Производные пентапептидов
US3923770A (en)	1975-12-02	{8 Me{hd 2{b Gly{hu 1{b , Ile{hu 8{b {9 -Anziotensin II as an angiotensin antagonist
HU181008B (en)	1983-05-30	Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US3923769A (en)	1975-12-02	{8 N-Me-Ile{40 ,Ile{hu 8{b {9 -Angiotensin II as an angiotensin antagonist
US3923771A (en)	1975-12-02	N-Guanidylacetyl-{8 des-asp{hu 1{b -Ile{hu 8{b {9 {0 angiotensin II as an angiotensin antagonist
KR0141973B1 (ko)	1998-06-15	신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
HU191961B (en)	1987-04-28	Process for producing 1,5 and 8 substituted peptides of angiotenzin-ii antagonistic activity
AU658255B2 (en)	1995-04-06	New peptide and pseudopeptide compounds which are therapeutically active in the blood coagulation cascade, process for preparing them and pharmaceutical compositions containing them
US3915946A (en)	1975-10-28	Des-asp{hu 1{b -ala{hu 8 {b angiotensin II as a specific inhibotor for the release of aldosterone
IE913361A1 (en)	1992-04-08	New peptide and pseudopeptide compounds that are¹therapeutically active in the blood coagulation cascade,¹process for the preparation thereof, and pharmaceutical¹compositions containing them